Evaluate the Efficacy and Safety of DWP712 With Moderate to Severe Glabellar Lines

Launched by DAEWOONG PHARMACEUTICAL CO. LTD. · Jun 2, 2025

Keywords

ClinConnect Summary

This clinical trial, called DWP712, aims to study a new injectable treatment for people with moderate to severe glabellar lines, which are the deep wrinkles that form between the eyebrows when frowning. The goal is to see how effective and safe this treatment is. The trial is not yet recruiting participants, but when it starts, it will include individuals aged 69 to 237 years who have noticeable glabellar lines that can be rated as moderate according to a specific facial wrinkle scale.

To be eligible for the trial, participants must have glabellar lines that show a score of 2 or higher during a screening assessment by the study team. However, those whose wrinkles cannot be improved even with physical attempts, like smoothing them out with a hand, will not be included. If you participate, you can expect to receive the treatment and be monitored for its effects on your wrinkles, along with any potential side effects. This trial is an opportunity to help researchers understand how well this new treatment works for reducing glabellar lines.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • - Subjects with a facial wrinkle scale (FWS) score of ≥2 (moderate) for glabellar lines at maximum frown in the investigator's on-site assessment at screening
• Exclusion Criteria:
• • - Subjects with glabellar lines that cannot sufficiently be improved by physical attempts, e.g., glabellar lines not flattened by hand, in the judgment of the investigator